Sign in
SuspendedPhase 3

The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients

Key facts

Who runs it
University Hospital, Brest
Where
France10 sites in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
Phase
Phase 3
People taking part
370 people, planned
Started
15 Mar 2022
Expected to end
26 Apr 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Naloxegol
  • Placebo
Record updated
16 June 2026
Why it stopped
interim analysis - Results ongoing

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age ≥ to 18 years old
  • Admission to intensive care unit for traumatic brain injury or subarachnoid hemorrhage without other life-threatening injury
  • Patients under sedation with administration of opiate-agonists, μ receptor agonists (Sufentanil, Fentanyl, Remifentanil, Morphine) for less than 24 hours
  • Expected duration of invasive mechanical ventilation and sedation of 48 hours or more
  • Intracranial pressure monitoring
  • Enteral feeding by oro / nasogastric tube
  • Affiliated or beneficiary of the French social security system

Who cannot take part

  • Patient who received opioids for more than 24 hours
  • Concomitant treatment with a strong or moderate inhibitory effect of CYP 3A4 (For example: clarithromycin, ketaconazole, itraconazole, telithromycin, ritonavir, indinavir, saquinavir) or with a strong inducing effect (carbamazepin, rifampicin, millepertuis)
  • Concomitant treatment with vascular endothelial growth factor (VEGF) inhibitor
  • Patient with refractory intracranial hypertension at the time of inclusion: intracranial hypertension requiring therapy other than analgo-sedation (thiopental, targeted temperature management, decompressive craniectomy)
  • Risk of digestive perforation:; history of peptic ulcer; Crohn's disease; Ogilvie syndrome; acute diverticulitis; infiltrating gastrointestinal tumor; recurrent or advanced ovarian cancer; peritoneal metastasis; recent abdominal trauma with risk of digestive perforation
  • Allergy to Naloxegol or one of its excipients
  • History of clinically important alterations of the blood-brain barrier: primary brain tumors, metastasis or other inflammatory pathologies in the CNS, active multiple sclerosis, Alzheimer's disease at an advanced stage
  • Acute or chronic renal failure with creatinine clearance <60ml / min
  • Recent history of myocardial infarction within the past 6 months, symptomatic congestive cardiovascular disease, QT ≥ 500 msec
  • Known or suspected acute gastrointestinal obstruction
  • Patient with a medical decision for rapid palliative care
  • Pregnancy and / or breastfeeding
  • Child Pugh C stage cirrhosis
  • Patient under legal protection or deprived of liberty
  • Patient with another life-threatening injury

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Impaired gastrointestinal transit (IGT) especially constipation, is common among patients under mechanical ventilation, occurring in up to 80 % of the patients during the first week, and has been associated with worse outcome in intensive care unit (ICU). Although IGT in critically ill patients is multifactorial and some components are due to complex disease, there is increasing evidence that exogenous opioids contribute to bowel dysmotility.

Read full original descriptionShow less

Sedatives and especially opioids are largely used in the brain injured population to control intracranial pression, reduce metabolic rate, manage or prevent seizures, and improve mechanical ventilator synchrony. Therefore, brain injured patients are particularly at risk to develop IGT. The occurrence of IGT is associated with adverse outcomes in intensive care unit. Both gastric reflux and impaired peristaltic contractions are associated with ventilator-acquired pneumonia.

The actual challenge is to prevent motility disorders before it occurs. A preventive strategy could in turn reduce the occurrence of complications related to impaired gastrointestinal transit such as ventilator-acquired pneumonia, bacteremia etc. It could also reduce the complications of feed intolerance and thus reduce morbidity and mortality in ICU.

Naloxegol is a polyethylene glycol derivative of naloxol, which is a derivative of naloxone and a peripherally acting µ-opioid receptor antagonist. Contrary to naloxone, naloxegol has a very low penetration into the central nervous system, therefore it could be a relevant option for ileus prevention without the risk of impaired sedation.

The aim of our study is to assess the efficacy of the administration of naloxegol on the onset of early constipation and early ventilator-acquired pneumonia in brain injured patients receiving opioids for analgosedation.

The 2 groups in the trial

  • NaloxegolTreatment being tested

    Administration of Naloxegol 25 mg per day by nasogastric tube (NG) or orogastric tube (OG). The administration should be started within the first 24 hours after the patient is admitted to intensive care unit and continued for the duration of the administration of the morphine derivative and until 48 hours after its discontinuation. Management of constipation and gastroparesis according to the recommendations.

  • PlaceboPlacebo, for comparison

    Administration of the placebo according to the same procedures as the experimental arm.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The NIPA Study: A Randomized Double-blind Control Clinical Trial Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients
Record updated
16 June 2026